Conclusion The development of retatrutide, a novel triple-hormone receptor agonist, has generated significant interest in weight management
The connection runs both ways: Carolyn Bottone-Post, CNM, DNP, FACNM one of our two providers is also an Associate Professor at the University of Northern Colorado School of Nursing in Greeley, where she trains the next generation of nurse practitioners
Recognizing Individual Risk Factors: Individuals with underlying health conditions such as hypertension, diabetes, sleep apnea, or cardiovascular disease may already be at a much higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION)
For instance, Ozempic is only approved in the UK as a treatment for type 2 diabetes, not as a weight loss medication